888-969-2592
Kalkine 0
countryflagCA

Spectral Med Inc

Healthcare CA EDT

0.87CAD
-(-%)

Last update at 2025-05-09T16:19:00Z

Day Range

0.860.87
LowHigh

52 Week Range

0.330.75
LowHigh

Fundamentals

  • Previous Close 0.87
  • Market Cap147.06M
  • Volume27320
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-12.12400M
  • Revenue TTM1.90M
  • Revenue Per Share TTM0.007
  • Gross Profit TTM 0.98M
  • Diluted EPS TTM-0.07

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -9.59300M -8.78500M -9.09800M -4.86000M -2.48900M
Minority interest - - - - -
Net income -11.29900M -8.94100M -9.07500M -4.97400M -3.38200M
Selling general administrative 8.01M 9.43M 10.11M 6.70M 4.88M
Selling and marketing expenses - - - - -
Gross profit 0.98M 1.22M 1.47M 2.22M 3.47M
Reconciled depreciation 0.27M 0.29M 0.30M 0.28M 0.23M
Ebit -9.44000M -8.60100M -9.08900M -4.71000M -1.59600M
Ebitda -9.16800M -8.30700M -8.78500M -4.43200M -1.36600M
Depreciation and amortization 0.27M 0.29M 0.30M 0.28M 0.23M
Non operating income net other - - - - -
Operating income -9.44000M -8.60100M -9.08900M -4.71000M -1.59600M
Other operating expenses 8.92M 10.56M 11.04M 7.63M 5.59M
Interest expense 0.10M 0.03M 0.03M 0.04M 0.89M
Tax provision - - - - -
Interest income - - - 0.08M -
Net interest income -0.10400M -0.02800M -0.03200M 0.04M -
Extraordinary items -3.65300M - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 1.71M 0.16M -0.02300M 0.11M 0.89M
Total revenue 1.67M 2.05M 2.10M 2.87M 3.84M
Total operating expenses 8.23M 9.73M 10.41M 6.98M 5.22M
Cost of revenue 0.68M 0.83M 0.63M 0.65M 0.37M
Total other income expense net -0.15300M -0.18400M -0.00900M -0.15000M -0.89300M
Discontinued operations -3.65300M -3.65300M -3.65300M -3.65300M -
Net income from continuing ops -9.59300M -8.78500M -9.09800M -4.86000M -2.48900M
Net income applicable to common shares -11.25000M -8.78500M -9.09800M -4.86000M -2.48900M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 5.21M 12.00M 11.55M 8.16M 4.01M
Intangible assets 0.19M 0.21M 0.23M 0.25M 0.26M
Earning assets - - - - -
Other current assets 0.62M 0.28M 0.97M 0.39M 0.15M
Total liab 21.76M 14.52M 7.47M 8.83M 1.75M
Total stockholder equity -16.54900M -2.52300M 4.08M -0.66900M 2.26M
Deferred long term liab - - - - -
Other current liab 7.53M 1.52M 1.08M 0.98M 0.70M
Common stock 87.06M 87.05M 84.36M 71.87M 66.84M
Capital stock 87.06M 87.05M 84.36M 71.87M 66.84M
Retained earnings -125.43700M -109.74400M -98.49400M -89.70900M -80.61100M
Other liab - 4.01M 4.68M 5.35M -
Good will - - - - -
Other assets - - - - -
Cash 2.95M 8.41M 8.89M 5.81M 1.44M
Cash and equivalents - - - - -
Total current liabilities 10.24M 3.96M 2.30M 2.90M 1.08M
Current deferred revenue 0.73M 0.70M 0.69M 0.68M -
Net debt 5.61M -1.76900M -8.30800M -5.14000M -0.69100M
Short term debt 0.39M 0.10M 0.09M 0.09M 0.08M
Short long term debt 0.26M - - - -
Short long term debt total 8.56M 6.64M 0.58M 0.67M 0.74M
Other stockholder equity 8.92M 20.17M 18.22M 17.17M 16.03M
Property plant equipment - 0.70M 1.06M 1.11M 1.09M
Total current assets 4.12M 10.09M 10.26M 6.80M 2.66M
Long term investments 0.00000M 1.00M - - -
Net tangible assets - -2.73400M 3.85M -0.91500M 2.00M
Short term investments 0.61M - - - 0.00400M
Net receivables 0.19M 1.06M 0.20M 0.26M 0.79M
Long term debt 7.68M 6.13M - - -
Inventory 0.37M 0.34M 0.29M 0.35M 0.28M
Accounts payable 1.60M 1.65M 0.44M 1.16M 0.30M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 12.91M - - -2.93300M -2.56600M
Additional paid in capital - - - - -
Common stock total equity - - - 71.87M 66.84M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - 1.35M
Deferred long term asset charges - - - - -
Non current assets total 1.09M 1.91M 1.29M 1.36M 1.35M
Capital lease obligations 0.62M 0.52M 0.58M 0.67M 0.74M
Long term debt total - 6.55M 0.49M 0.58M 0.67M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.03300M -0.32500M -0.29700M -0.16100M -0.04700M
Change to liabilities 0.96M -1.27500M 7.16M 0.40M -0.00800M
Total cashflows from investing activities -0.03300M -0.32500M -0.29700M -0.16100M -0.04700M
Net borrowings 6.71M -0.11300M -0.10900M -0.10500M -0.10500M
Total cash from financing activities 9.48M 12.16M 5.18M 0.02M 5.29M
Change to operating activities 0.60M -0.48600M -0.23400M 0.04M -0.11900M
Net income -11.25000M -8.78500M -9.09800M -4.86000M -2.48900M
Change in cash -0.47600M 3.08M 4.37M -2.93300M 2.92M
Begin period cash flow 8.89M 5.81M 1.44M 4.37M 1.45M
End period cash flow 8.41M 8.89M 5.81M 1.44M 4.37M
Total cash from operating activities -9.92800M -8.70100M -0.32400M -2.73800M -2.32200M
Issuance of capital stock 4.03M 10.00M 5.10M 0.00000M 5.31M
Depreciation 0.27M 0.29M 0.30M 0.28M 0.23M
Other cashflows from investing activities 0.00000M 0.16M 0.02M - -
Dividends paid - - - - -
Change to inventory -0.04700M -0.05100M -0.07200M -0.07900M -0.00600M
Change to account receivables -0.85100M 0.06M 0.01M 1.16M -0.55200M
Sale purchase of stock 4.11M 13.41M 6.08M 0.13M 5.40M
Other cashflows from financing activities 5.55M 2.28M 0.19M 0.13M -0.02000M
Change to netincome 0.39M 1.55M 1.08M 0.72M 0.69M
Capital expenditures 0.03M 0.48M 0.32M 0.16M 0.05M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.66M -1.75700M 7.39M 1.12M -0.81100M
Stock based compensation 1.20M 1.26M 0.88M 0.62M 0.71M
Other non cash items -0.80600M 0.29M 0.20M 0.10M 0.04M
Free cash flow -9.96100M -9.18400M -0.63900M -2.89900M -2.36900M

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
EDT
Spectral Med Inc		 - -% 0.87 - - 77.36 49.87 80.26 -7.5083
SZLS
StageZero Life Sciences Ltd		 - -% 0.04 - 3.37 1.70 5.94 2.34 -0.5648

Reports Covered

Stock Research & News

View All

Profile

Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.

Spectral Med Inc

135 The West Mall, Toronto, ON, Canada, M9C 1C2

Key Executives

Name Title Year Born
Mr. Christopher Seto CEO & Director NA
Dr. John A. Kellum M.D. Chief Medical Officer NA
Ms. Debra-Anne M. Foster B.Sc., RN, CCRC VP of Clinical Devel. NA
Mr. Blair McInnis Chief Financial Officer NA
Mr. Sam Amory Pres of Dialco Medical Inc. NA
Mr. Christopher Seto CEO, CFO & Director NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.